When you take a GLP-1 agonist, food stays in your stomach longer
The GLP-1RAs are achieving blockbuster status, meaning a drug that generates yearly sales exceeding one billion dollars for a drug company
Probiotic GLP-1 supplements as finished products have not been studied in published randomized controlled trials comparable to pharmaceutical research
Surprisingly, GLP-1RAs, such as liraglutide, lixisenatide, and semaglutide, have showed outstandingly neuroprotective effects on animal models of PD (63, 64)
TRIUMPH-3: Weight management in people with cardiovascular disease Additional TRIUMPH Trials: Type 2 diabetes management Chronic low back pain Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH/NAFLD) Cardiovascular and renal outcomes The TRIUMPH program has enrolled more than 5,800 participants total, making it one of the largest Phase 3 programs for an obesity medication in history